Drug Delivery Devices Market Is Set For Lucrative Growth To 2030

Drug Delivery Devices Market Summary

The global drug delivery devices market size was estimated at USD 432.4 billion in 2024 and is projected to reach USD 667.4 billion by 2030, growing at a CAGR of 7.5% from 2025 to 2030. The growing adoption of advanced technology for precise and controlled drug delivery is driving market expansion, as healthcare providers and pharmaceutical companies increasingly utilize innovative tools to improve treatment accuracy and enhance patient outcomes. These technologies help ensure that medications are delivered at the right dose and time, contributing to better therapeutic efficiency across a wide range of clinical applications.

In June 2024, Aptar Digital Health and SHL Medical partnered to enhance injectable therapy experiences by integrating Aptar’s SaMD platform with SHL’s connected drug delivery solutions, including the Molly Connected Cap. This collaboration aims to improve self-injection therapy through digital health innovations, enabling patients to monitor their progress and adhere more effectively to treatment plans. These advanced devices optimize drug delivery, minimize required dosage, and reduce potential side effects, ultimately lowering overall treatment costs by decreasing reliance on active pharmaceutical ingredients. As demand for novel and targeted drug delivery systems continues to rise, research and development activities in the sector are expected to accelerate further.

Key Market Trends & Insights

• The North America drug delivery devices market dominated the overall global market and accounted for 32.4% revenue share in 2024, supported by high healthcare spending, strong adoption of advanced medical technologies, and a growing prevalence of chronic diseases.
• The drug delivery devices market in the U.S. held a significant share of North America’s market in 2024 due to established healthcare infrastructure and increasing patient demand for convenient and effective delivery methods.
• By product, the inhalers segment led the market with a share of 23.9% in 2024, driven by the rising incidence of asthma, COPD, and other respiratory disorders.
• By application, the drug delivery devices segment for diabetes dominated the market in 2024 with a share of 21.1%, reflecting widespread use of insulin delivery devices and increasing diabetes prevalence.

Order a free sample PDF of the Drug Delivery Devices Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2024 Market Size: USD 432.4 Billion
• 2030 Projected Market Size: USD 667.4 Billion
• CAGR (2025-2030): 7.5%
• North America: Largest market in 2024

Key Companies & Market Share Insights

The competitive scenario in the drug delivery devices market is highly competitive, with key players such as Gerresheimer AG, Medtronic and Abbott holding significant positions. The major companies are undertaking various organic as well as inorganic strategies such as new product development, collaborations, acquisitions, mergers, and regional expansion for serving the unmet needs of their customers.

Key Players

• Gerresheimer AG
• L. Gore & Associates, Inc.
• Abbott
• Terumo Medical Corporation
• Stryker
• Medtronic
• Boston Scientific Corporation
• Novartis AG
• Becton, Dickinson and Company
• Teleflex Incorporated

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The drug delivery devices market is poised for steady expansion as advancements in digital health, connectivity, and precision medicine continue to reshape treatment approaches. Innovative collaborations among technology firms and medical device manufacturers are improving patient adherence, enhancing therapeutic accuracy, and reducing healthcare costs. Rising demand for user-friendly, self-administered devices, particularly for chronic diseases such as diabetes and respiratory disorders, will further strengthen market adoption. Regions like North America are expected to maintain strong momentum, while global R&D efforts accelerate development of next-generation solutions. Overall, the market will benefit from growing emphasis on personalized care, safety, and improved patient treatment experiences.